Compare Ginkgo Bioworks Holdings Inc (DNA) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Mattel Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.91 (market cap $772.39M), while Mattel Inc trades at $16.7 (market cap $4.74B). The key difference: Mattel Inc is far larger — about 6.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Mattel Inc for 97 Days on average.
| DNA | MAT | |
|---|---|---|
Market Cap | $772.39M | $4.74B |
Volume | 6,453,273 | 11,809,722 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $22.16 |
52-Week Low | $5.48 | $12.66 |
Typical Hold Time | 7 Days | 97 Days |
Enterprise Value | $874.34M | $6.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Mattel (MAT) trades at $16.37, up 2.76% amid takeover speculation, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings but maintains solid profitability with a 7.78% net income margin and a reasonable P/E of 12.22. Recent news highlights CEO transition and acquisition interest from Authentic Brands Group, potentially valuing the firm around $6 billion.
The stock's outlook is supported by strong analyst sentiment (52.94% buy ratings) and a stable financial base, though risks include earnings volatility and leadership changes. Near-term price action hinges on takeover developments and new CEO execution, with the consensus price target at $15.00 suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
